GIPR antagonism plus GLP-1R agonism delivered as a single antibody-peptide conjugate. Monthly subcutaneous dosing.
Reference facts
- Also known as
- AMG 133, Maridebart cafraglutide
- Category
- GLP-1 & Metabolic
- Mechanism of action
- GIPR antagonism plus GLP-1R agonism delivered as a single antibody-peptide conjugate. Monthly subcutaneous dosing.
- Targets
- GIPR (antagonist), GLP-1R (agonist)
- Indications under research or approved
- Obesity, Type 2 Diabetes
- Regulatory status (reference entry)
- Investigational (Phase 3 MARITIME)
- Half-life
- ~21 days
- Sequence notes
- Peptide-antibody conjugate: monoclonal anti-GIPR antibody covalently linked to two GLP-1 analog peptides via stable conjugation.
- Molecular weight (Da)
- 150000
- Originator / sponsor
- Amgen
- First reported
- 2023
Primary References
Explore research articles about MariTide
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.